Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$177M in Q4 2025 → $176M now. Hover for any quarter.
As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| KM Kestra Med Technologies Ltd | 43.9% | Unchanged | 2,728,679 | $77.2M |
| Mineralys Therapeutics Inc | 22.8% | Unchanged | 1,591,917 | $40M |
| AP Avalyn Pharmaceuticals Inc | 15.1% | Unchanged | 929,824 | $26.5M |
| Agomab Therapeutics Nv | 9.7% | Unchanged | 1,538,702 | $17.1M |
| Inventiva Sa | 7.6% | Unchanged | 3,633,181 | $13.4M |
| Evommune Inc | 0.5% | Trimmed 93% | 97,362 | $804K |
| NS Nyxoah S A | 0.4% | Unchanged | 522,057 | $720K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2026 · filed October 16, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Evommune Inc | Trimmed | −1,294,628 | −$10.7M | 0.5% |
| Abivax Sa | Exited | −78,125 | −$10.4M | — |
quarter ended June 30, 2026 · filed July 22, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AP Avalyn Pharmaceuticals Inc | New | +929,824 | +$30.6M | 14.8% |
| Inventiva Sa | Added | +1,815,000 | +$6.86M | 6.7% |
| Evommune Inc | Trimmed | −505,372 | −$6.72M | 9.0% |
| KM Kestra Med Technologies Ltd | Added | +33,487 | +$852K | 33.6% |
quarter ended March 31, 2026 · filed May 11, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Agomab Therapeutics Nv | New | +1,538,702 | +$16.1M | 9.1% |
| KM Kestra Med Technologies Ltd | Added | +155,086 | +$3.09M | 30.4% |
| NS Nyxoah S A | New | +522,057 | +$1.52M | 0.9% |
Loading...
